Abdullah bin Ahmed I
If there is a rebound weight, we have a problem, because we're going to create the same problems that we started with, says Pinto
With significant results of GLP-1 receptor agonists in clinical trials , such as weight loss (up to 20%) and improved glycemic control, making them a preference for both physicians and patients
Non-inferiority was proven for IDegLira compared to degludec (A1c 0.47%
A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe
Originally derived from a protein found in the human stomach, BPC-157 (Body Protection Compound-157) is a synthetic peptide known for promoting tissue repair, reducing inflammation, and supporting gut, muscle, and even brain health